Martin L. Lee

Martin L. Lee has spent more than 45 years in the pharmaceutical, medical device, biotech and nutraceutical industries. In those years he has been head of clinical research, regulatory affairs, quality control and biostatistics. He has reached levels of Director, Vice President and Senior Vice President. During his tenure he has overseen landmark achievements in various medical fields including the introduction of the first immunotherapeutic for Guillain-Barre Syndrome, the first recombinant DNA-produced Factor VIII preparation for individuals with hemophilia A, the first completely human milk-based fortifier for extremely premature infants, and a fibrinogen/thrombin based surgical adhesive for the treatment of severe burns and the promotion of wound healing. In addition, his work has involved the study of novel therapeutic biologics for the treatment of chronic lymphocytic leukemia, multiple myeloma, SLE, rheumatoid arthritis, Type 1 and 2 diabetes, hemophilia B and other rare bleeding disorders, and Stage 4 melanoma.

He is Adjunct Professor of Biostatistics in the Fielding School of Public Health at UCLA (since 1979) and Professor of Internal Medicine, Charles R. Drew University of Science and Medicine (since 2000). He is the author or coauthor of over 275 scientific papers and is a Fellow of the Royal Statistical Society. Dr. Lee is a Chartered Statistician and a Chartered Scientist as designated by the Royal Statistical Society and a Fellow of the Institute of Biomedical Sciences. Dr. Lee received the B.A. (1974) degree in mathematics, and the M.S. (1975) and the Ph.D. (1979) degrees in biostatistics with a minor in biological chemistry from the University of California, Los Angeles.